All In Biotech

NDA 207318 · Acadia Pharms INC

Nuplazid

Pimavanserin Tartrate · Oral

NovelBreakthrough therapyPriority review

Last checked: Nov 20, 2026Latest source record: Apr 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Apr 29, 2016

Approved uses

4

Original approval plus efficacy supplements

Registered trials

45

15 Phase 3, 10 recruiting

FAERS reports

57,532

29,715 serious, 14,647 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson's disease [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning . Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson's disease. ( 5.1 )

What it is approved for

From the label in effect Jun 18, 2026.

NUPLAZID ® is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis [ see Clinical Studies (14) ] . NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ( 1 )

Mechanism: The mechanism of action of pimavanserin in the treatment of hallucinations and delusions associated with PDP is unclear. However, the effect of pimavanserin could be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT 2A receptors and to a lesser extent at serotonin 5-HT 2C receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 27, 2026 Supplement 16 · Efficacy · priority review LetterLabel
  • Sep 15, 2023 Supplement 12 · Efficacy LetterLabel
  • Jun 28, 2018 Supplement 3 · Efficacy LetterLabel
  • Apr 29, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelSummary ReviewLetter
2 products under this application
  • NUPLAZID · PIMAVANSERIN TARTRATE EQ 17MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • NUPLAZID · PIMAVANSERIN TARTRATE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Pimavanserin" as an intervention, any sponsor and status, largest first.

All 45 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hallucination13,278
  • death11,261
  • drug ineffective6,630
  • confusional state4,448
  • product dose omission issue4,364
  • fall4,197
  • delusion2,852
  • condition aggravated2,605
  • hallucination, visual2,413
  • parkinson^s disease2,350
  • gait disturbance2,289
  • urinary tract infection1,923

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20152
20161,269
20174,548
20184,467
20192,606
20205,917
20214,703
20224,300
20234,501
20247,184
202510,493
20267,542

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nuplazid (Pimavanserin Tartrate)

2024 spending

$658M

Beneficiaries

17,122

143,328 claims

Per beneficiary

$38,420

$165.57 per unit

View as table
YearSpending
2020$416,044,322
2021$470,863,042
2022$528,932,689
2023$595,675,170
2024$657,826,493

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 46 on PubMed

Sponsor: Acadia Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.